|
Federal Sudden Unexpected Infant Death/Sudden Infant Death Syndrome (SUID/SIDS) Workgroup
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, HRSA, IHS
|
NICHD
|
The purpose of the partnership is to establish and enhance relationships among Federal agencies with responsibilities for SIDS and SUID. The partner agencies intend to work together to improve communication and coordination, and to collaborate on a range of activities designed to reduce, and, ultimately, eliminate SIDS and SUID, including the elimination of racial, ethnic and socio-economic disparities.
|
|
Federal Supply and Demand of Isotopes
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIBIB, NCI
|
A workshop on Isotope Federal Supply and Demand is held annually. The workgroup that organizes this workshop consists of representatives of federal agencies with the aim of providing a forum for interaction between agencies, departments, and medical societies to communicate about potential shortages of isotopes that are of strategic importance to the nation including the availability of medical isotopes. Also, a report of isotope supply and demand and whether needs are commercially available is compiled by National Institutes of Health (NIH) and submitted to DOE annually. The report includes demand for NIH intramural research programs and NIH extramural projects (grantees). Not included in this report are NIH intramural research needs that are supplied by its cyclotron or isotope needs met by commercial suppliers. NIH collects data from ICs and submits annual report as required. On January 12, 2021, DOE, NIH, and the members of the Isotope Needs Program held the 7th Workshop on Isotope Federal Supply and Demand. The meeting reviewed the Program’s ongoing activities and reported that the newly evolving use of electron- and alpha-emitting isotopes is seeing increased need (based on FDA’s approval for medical applications); the DOE is developing a plan to meet the current and foreseen increased use of these isotopes for cancer therapy. https://web.cvent.com/event/090a6518-df28-4afc-8a3e-f972dd76c397/websit…
|
|
Federal Tuberculosis (TB) Task Force
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, IHS, OS
|
NICHD, NIAID
|
The Federal Tuberculosis (TB) Task Force is a coalition composed of the federal agencies involved in U.S. TB research and control efforts. Established in 1991, it facilitates coordination of activities among these federal agencies.
|
|
Federal Working Group on Bone Diseases
|
Committee, Work group, Advisory group, or Task Force
|
CDC, CMS, FDA
|
NIAMS, CSR, NCATS, NCI, NEI, NIA, NIAID, NICHD, NIDCR, NIDDK, OD/DPCPSI, OD/DPCPSI/ORWH
|
An interagency committee focusing on osteoporosis and other bone disorders. It offers a forum for sharing information, learning from each other and invited speakers, and facilitating the development, early in the planning stages, of collaborative research activities based on each agency's mission.
|
|
Federal Working Group on Dietary Supplements (FWGoDS)
|
Meeting/ Workshop
|
AHRQ, CDC, HRSA, IHS, FDA
|
NCATS, CC, FIC, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCR, NIDDK, NIDA, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NINR, NLM
|
The Federal Working Group on Dietary Supplements (FWGoDS) consists of representatives from federal agencies that share information and discuss issues, initiatives, and research related to dietary supplements. The FWGoDS serves as means of communication between the Office of Dietary Supplements (ODS) and its federal partners in several ways:
1) to co-fund research investigations within the National Institutes of Health (NIH);
2) to expand opportunities for research-investigator training; and
3) to strengthen collaborative efforts involving dietary supplement research, education, and communication across the government.
The FWGoDS was established in part on the basis of a Congressional law which specifies that ODS serve as an advisor to federal health agencies on issues related to dietary supplements. It also exists in response to a goal in the ODS Strategic Plan to expand and conduct outreach efforts that inform and educate about supplements.
The FWGoDS has met twice a year since 2005, generally in April and October. It also maintains periodic contact via email and other means as appropriate.
|
|
federated learning across Health Information Exchanges (HIE)
|
Committee, Work group, Advisory group, or Task Force
|
ONC
|
NCI
|
In cooperation with the Nebraska Health Information Initiative (NEHII) and the National Cancer Institute (NCI), NIH launched a pilot program earlier this year that uses a machine learning concept known as federated learning that could leverage existing HIE data while ensuring privacy. Federated learning is a machine learning technique that shares an analytical model between different groups, allowing them to analyze their own data – and share those results – without needing to share the actual raw data.
The pilot aimed to expand clinical insights regarding COVID-19 using the existing ways health data are stored and protected in the US. In our pilot, each organization connected to a central cloud ecosystem known as the Multi-state Federated Architecture for Shared Analytics, better known as MuFASA.
|
|
Filovirus Animal Non-Clinical Group (FANG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The FANG focuses on the product development tools and other interagency product development issues relevant to FDA approval of filovirus MCM. A standing interagency working group, the Portfolio Advisory Committee, oversees the FANG. The FANG will develop strategies to address broadly applicable and interagency product development issues relevant to licensure of filovirus MCM. The FANG will develop consensus recommendations to facilitate standardization of reagents, methods, and procedures across multiple agencies and laboratories.
|
|
Filovirus Animal Non-Clinical Group (FANG) Workshop
|
Meeting/ Workshop
|
CDC, FDA, OS
|
NIAID
|
The Filovirus Animal Non-Clinical Group (FANG) focuses on the advanced development of Filovirus medical countermeasures (MCM), both vaccines and therapeutics. The primary focus of the Workshop will be on Marburg virus, although other filoviruses will also be addressed.
|
|
FNIH Advanced Medicines Partnership on Gene Therapy
|
Research Initiative
|
FDA
|
NCATS
|
Working with the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) and FNIH to develop an Accelerated Medicines Partnership (AMP) on the topic of AAV gene therapy.
|
|
FNIH Biomarkers Consortium
|
Research Initiative
|
CMS, FDA
|
NIMH, NCATS, NCI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCR, NIDDK, NIEHS, NINDS
|
The Biomarkers Consortium is a major public-private biomedical research partnership managed by the Foundation for the National Institutes of Health (FNIH) with broad participation from stakeholders across the health field, including government, industry, academia, patient advocacy, and other not-for-profit organizations. In addition to the FNIH, founding members include the National Institutes of Health, Food and Drug Administration, and the Pharmaceutical Research and Manufacturers of America. The Biomarkers Consortium brings together the expertise and resources of various partners to rapidly identify, develop, and qualify potential high-impact biomarkers to enable improvements in drug development, clinical care, and regulatory decision-making.
|